A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Status:
Recruiting
Trial end date:
2022-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo
as a preventive treatment for migraine, as measured by the reduction in the number of
migraine days per month.